Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Research into the medical benefits of hallucinogenic drugs is back in vogue after being avoided by mainstream scientists for decades.

A team of researchers at Johns Hopkins University in Baltimore this week released the follow-up results of a study involving 36 volunteers who were given psilocybin - the chemical ingredient in "sacred" or "magic" mushrooms - in a carefully controlled laboratory setting.

A questionnaire completed 14 months after the one-day drug trial found the majority of participants considered the experience to be one of the most "personally meaningful and spiritually significant" events of their lives. Even more surprising, they felt the drug had a long-lasting effect that significantly contributed to their overall sense of well-being and life satisfaction.

Story continues below advertisement

"I think we are into a new era of research," said Matthew Johnson, one of the authors of the study published in the Journal of Psychopharmacology.

He noted that it used to be common for researchers to explore the potential therapeutic uses of a wide range of hallucinogenic drugs including psilocybin, LSD and DMT. But the drug excesses of the psychedelic 1960s tarnished the legitimate research, and the trials were brought to a halt.

Now, a small but growing number of scientists in the United States and Europe are once again recruiting patients for studies of the controversial drugs.

Dr. Johnson said the mind-altering aspects of hallucinogens could possibly help cancer patients come to terms with their impending death. The drugs might also assist people overcoming certain addictions through greater self-awareness.

Still, there is a risk the drugs could also trigger anxiety and paranoia - basically "a bad trip" - and special precautions must be taken to safeguard the participants.

For instance, the Johns Hopkins researchers, led by Roland Griffiths, carefully screened volunteers to ensure that only psychologically stable individuals were selected. And during the study, participants were closely supervised and never left alone.

"They were given an opportunity for self-exploration," Dr. Johnson explained. "They were invited to just relax and experience their inner self while they were monitored by trained professionals in a completely safe environment," he said.

Story continues below advertisement

Although psilocybin is an illicit drug, it has been used in religious ceremonies of some cultures for centuries.

Dr. Johnson believes 60 per cent of participants had a "full mystical experience" partly because they were in a supportive environment and partly because they were religiously or spiritually inclined individuals.

"Many people have used magic mushrooms recreationally," he said. "Although some have reported experiences like this, plenty of them have not."

The research lab, which was made to resemble a comfortable living room, provided "a much more serious, introspective context compared to what is the norm for recreational drug use," he said. "Someone might take the same drug at a rock concert and just be completely distracted or engulfed in the external experience."

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies